Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
ConditionPancreatic Ductal Adenocarcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCity of Hope Medical Center
About this trial
This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
Eligibility criteria
Qualifiers
Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).
Underwent neoadjuvant chemotherapy (FOLFIRINOX or Gemcitabine/nab-paclitaxel).
Availability of pre-treatment plasma samples.
Underwent curative-intent resection (R0 or R1).
Disqualifiers
Inadequate plasma samples or poor RNA quality for exosomal miRNA analysis.
Non-adenocarcinoma histology.
Presence of synchronous or multiple primary malignancies.
Receipt of chemotherapy regimens other than standard FOLFIRINOX or gemcitabine plus nab-paclitaxel (GEM-NABP).
Trial design
Treatments tested in this trial
- Small RNA sequencing
- PRECEPT assay (qRT-PCR validation)
Treatment groups
200 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov